Compare · BDX vs SOLY
BDX vs SOLY
Side-by-side comparison of Becton Dickinson and Company (BDX) and Soliton, Inc. (SOLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SOLY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.79B, about 97.4x SOLY ($449.6M).
- BDX has hit the wire 4 times in the past 4 weeks while SOLY has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 0 for SOLY).
- Company
- Becton Dickinson and Company
- Soliton, Inc.
- Price
- $158.88+1.60%
- $22.59+0.16%
- Market cap
- $43.79B
- $449.6M
- 1M return
- +4.94%
- -
- 1Y return
- -13.15%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Soliton, Inc.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas.
Latest BDX
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Mike Garrison to Retire from BD
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
Latest SOLY
- SEC Form 15-12B filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form SC 13D/A filed by Soliton, Inc. (Amendment)
- SEC Form 4: Remeditex Ventures Llc returned $208,242,660 worth of shares to the company (9,214,277 units at $22.60)
- SEC Form 4: Tanner Joe D returned $1,808,000 worth of shares to the company (80,000 units at $22.60), closing all direct ownership in the company
- SEC Form 4: Klemp Walter V returned $9,605,000 worth of shares to the company (425,000 units at $22.60), closing all direct ownership in the company
- SEC Form 4 filed by Kaminer Michael S.
- SEC Form 4 filed by Hunt Niquette L.